Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis
- 24 February 2015
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 29 (8) , 1676-1683
Abstract
Natural killer (NK) cells are cytotoxic lymphocytes that substantially contribute to the therapeutic benefit of antitumor antibodies like Rituximab, a crucial component in the treatment of B-cell malignancies. In chronic lymphocytic leukemia (CLL), the ability of NK cells to lyse the malignant cells and to mediate antibody-dependent cellular cytotoxicity upon Fc receptor stimulation is compromised, but the underlying mechanisms are largely unclear. We report here that NK-cells activation-dependently produce the tumor necrosis factor family member ‘B-cell activating factor’ (BAFF) in soluble form with no detectable surface expression, also in response to Fc receptor triggering by therapeutic CD20-antibodies. BAFF in turn enhanced the metabolic activity of primary CLL cells and impaired direct and Rituximab-induced lysis of CLL cells without affecting NK reactivity per se. The neutralizing BAFF antibody Belimumab, which is approved for treatment of systemic lupus erythematosus, prevented the effects of BAFF on the metabolism of CLL cells and restored their susceptibility to direct and Rituximab-induced NK-cell killing in allogeneic and autologous experimental systems. Our findings unravel the involvement of BAFF in the resistance of CLL cells to NK-cell antitumor immunity and Rituximab treatment and point to a benefit of combinatory approaches employing BAFF-neutralizing drugs in B-cell malignancies.Keywords
This publication has 48 references indexed in Scilit:
- Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activityBlood, 2013
- Aberrant Expression of Functional BAFF-System Receptors by Malignant B-Cell Precursors Impacts Leukemia Cell SurvivalPLOS ONE, 2011
- Innate or Adaptive Immunity? The Example of Natural Killer CellsScience, 2011
- The clinical application of monoclonal antibodies in chronic lymphocytic leukemiaBlood, 2010
- RituximabDrugs, 2010
- A Functional Receptor for B-Cell–Activating Factor Is Expressed on Human Acute Lymphoblastic LeukemiasCancer Research, 2010
- CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cellsBlood, 2010
- Glucocorticoid-induced Tumor Necrosis Factor Receptor Negatively Regulates Activation of Human Primary Natural Killer (NK) Cells by Blocking Proliferative Signals and Increasing NK Cell ApoptosisJournal of Biological Chemistry, 2008
- BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-κB pathwayBlood, 2006
- Scoring proteomes with proteotypic peptide probesNature Reviews Molecular Cell Biology, 2005